中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

远端胆管癌非手术治疗的研究进展

陈姗姗 李威

陈姗姗, 李威. 远端胆管癌非手术治疗的研究进展[J]. 临床肝胆病杂志, 2021, 37(7): 1729-1732. DOI: 10.3969/j.issn.1001-5256.2021.07.053
引用本文: 陈姗姗, 李威. 远端胆管癌非手术治疗的研究进展[J]. 临床肝胆病杂志, 2021, 37(7): 1729-1732. DOI: 10.3969/j.issn.1001-5256.2021.07.053
CHEN SS, LI W. Research advances in non-surgical treatment of distal cholangiocarcinoma[J]. J Clin Hepatol, 2021, 37(7): 1729-1732. DOI: 10.3969/j.issn.1001-5256.2021.07.053
Citation: CHEN SS, LI W. Research advances in non-surgical treatment of distal cholangiocarcinoma[J]. J Clin Hepatol, 2021, 37(7): 1729-1732. DOI: 10.3969/j.issn.1001-5256.2021.07.053

远端胆管癌非手术治疗的研究进展

DOI: 10.3969/j.issn.1001-5256.2021.07.053
基金项目: 

首都卫生发展科研专项 2020-2-2175

详细信息
    通讯作者:

    李威, weili8989@ccmu.edu.cn

  • 中图分类号: R735.8

Research advances in non-surgical treatment of distal cholangiocarcinoma

Funds: 

Capital's Funds for Health Improvement and (CFH) 2020-2-2175

  • 摘要: 远端胆管癌是肝外胆管细胞癌的一种类型, 侵袭性高, 预后较差。由于早期检出率低, 大部分患者确诊时已是中晚期。随着近年来介入、消融、光动力等医疗技术不断改进, 化疗、靶向、免疫等药物治疗进一步研发, 非手术治疗方式在远端胆管癌综合治疗中的作用愈发受到关注。简述了远端胆管癌在局部治疗和系统治疗方面的研究进展, 归纳总结相关文献表明, 局部治疗可以解除胆道梗阻、减轻肿瘤负荷、提高生存质量; 系统治疗可以抑制肿瘤生长、减少术后复发、延长生存时间。根据患者个体化情况, 结合各种非手术治疗制订不同的综合诊治方案, 可以为不可切除远端胆管癌患者提供更多有效的治疗选择。

     

  • [1] HOYOS S, NAVAS MC, RESTREPO JC, et al. Current controversies in cholangiocarcinoma[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(4 Pt B): 1461-1467. DOI: 10.1016/j.bbadis.2017.07.027.
    [2] LEE RM, MAITHEL SK. Approaches and outcomes to distal cholangiocarcinoma[J]. Surg Oncol Clin N Am, 2019, 28(4): 631-643. DOI: 10.1016/j.soc.2019.06.014.
    [3] KOMAYA K, EBATA T, SHIRAI K, et al. Recurrence after resection with curative intent for distal cholangiocarcinoma[J]. Br J Surg, 2017, 104(4): 426-433. DOI: 10.1002/bjs.10452.
    [4] ZHOU Y, LIU S, WU L, et al. Survival after surgical resection of distal cholangiocarcinoma: A systematic review and meta-analysis of prognostic factors[J]. Asian J Surg, 2017, 40(2): 129-138. DOI: 10.1016/j.asjsur.2015.07.002.
    [5] WITZIGMANN H, LANG H, LAUER H. Guidelines for palliative surgery of cholangiocarcinoma[J]. HPB (Oxford), 2008, 10(3): 154-160. DOI: 10.1080/13651820801992567.
    [6] NAGINO M, HIRANO S, YOSHITOMI H, et al. Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition[J]. Chin J Dig Surg, 2021, 20(4): 359-375. DOI: 10.3760/cma.j.cn115610-20210303-00107.

    NAGINO M, HIRANO S, YOSHITOMI H, 等. 胆道肿瘤临床实践指南(英文第三版)[J]. 中华消化外科杂志, 2021, 20(4): 359-375. DOI: 10.3760/cma.j.cn115610-20210303-00107.
    [7] MIURA F, SANO K, WADA K, et al. Prognostic impact of type of preoperative biliary drainage in patients with distal cholangiocarcinoma[J]. Am J Surg, 2017, 214(2): 256-261. DOI: 10.1016/j.amjsurg.2017.01.010.
    [8] TAKAHASHI Y, NAGINO M, NISHIO H, et al. Percutaneous transhepatic biliary drainage catheter tract recurrence in cholangiocarcinoma[J]. Br J Surg, 2010, 97(12): 1860-1866. DOI: 10.1002/bjs.7228.
    [9] Chinese society of Clinical Oncology (CSCO) biliary tumor Expert Committee. Consensus of experts on diagnosis and treatment of biliary system tumor (2019 Edition)[J]. Chin Clin Oncol, 2019, 24(9): 828-838. DOI: 10.3969/j.issn.1009-0460.2019.09.014.

    CSCO胆道肿瘤专家委员会. CSCO胆道系统肿瘤诊断治疗专家共识(2019年版)[J]. 临床肿瘤学杂志, 2019, 24(9): 828-838. DOI: 10.3969/j.issn.1009-0460.2019.09.014.
    [10] SHARAIHA RZ, KHAN MA, KAMAL F, et al. Efficacy and safety of EUS-guided biliary drainage in comparison with percutaneous biliary drainage when ERCP fails: A systematic review and meta-analysis[J]. Gastrointest Endosc, 2017, 85(5): 904-914. DOI: 10.1016/j.gie.2016.12.023.
    [11] SOFI AA, KHAN MA, DAS A, et al. Radiofrequency ablation combined with biliary stent placement versus stent placement alone for malignant biliary strictures: A systematic review and meta-analysis[J]. Gastrointest Endosc, 2018, 87(4): 944-951. DOI: 10.1016/j.gie.2017.10.029.
    [12] WU TT, LI WM, LI HC, et al. Percutaneous intraductal radiofrequency ablation for extrahepatic distal cholangiocarcinoma: A method for prolonging stent patency and achieving better functional status and quality of life[J]. Cardiovasc Intervent Radiol, 2017, 40(2): 260-269. DOI: 10.1007/s00270-016-1483-2.
    [13] KIM EJ, CHUNG DH, KIM YJ, et al. Endobiliary radiofrequency ablation for distal extrahepatic cholangiocarcinoma: A clinicopathological study[J]. PLoS One, 2018, 13(11): e0206694. DOI: 10.1371/journal.pone.0206694.
    [14] STRAND DS, COSGROVE ND, PATRIE JT, et al. ERCP-directed radiofrequency ablation and photodynamic therapy are associated with comparable survival in the treatment of unresectable cholangiocarcinoma[J]. Gastrointest Endosc, 2014, 80(5): 794-804. DOI: 10.1016/j.gie.2014.02.1030.
    [15] SALGADO SM, GAIDHANE M, KAHALEH M. Endoscopic palliation of malignant biliary strictures[J]. World J Gastrointest Oncol, 2016, 8(3): 240-247. DOI: 10.4251/wjgo.v8.i3.240.
    [16] LAQUIERE A, BOUSTIERE C, LEBLANC S, et al. Safety and feasibility of endoscopic biliary radiofrequency ablation treatment of extrahepatic cholangiocarcinoma[J]. Surg Endosc, 2016, 30(3): 1242-1248. DOI: 10.1007/s00464-015-4322-7.
    [17] HORGAN AM, AMIR E, WALTER T, et al. Adjuvant therapy in the treatment of biliary tract cancer: A systematic review and meta-analysis[J]. J Clin Oncol, 2012, 30(16): 1934-1940. DOI: 10.1200/JCO.2011.40.5381.
    [18] BEN-JOSEF E, GUTHRIE KA, EL-KHOUEIRY AB, et al. SWOG S0809: A phase Ⅱ intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma[J]. J Clin Oncol, 2015, 33(24): 2617-2622. DOI: 10.1200/JCO.2014.60.2219.
    [19] GHAFOORI AP, NELSON JW, WILLETT CG, et al. Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma[J]. Int J Radiat Oncol Biol Phys, 2011, 81(3): 654-659. DOI: 10.1016/j.ijrobp.2010.06.018.
    [20] HYGHES MA, FRASSICA DA, YEO CJ, et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct[J]. Int J Radiat Oncol Biol Phys, 2007, 68(1): 178-182. DOI: 10.1016/j.ijrobp.2006.11.048.
    [21] FULLER CD, WANG SJ, CHOI M, et al. Multimodality therapy for locoregional extrahepatic cholangiocarcinoma: A population-based analysis[J]. Cancer, 2009, 115(22): 5175-5183. DOI: 10.1002/cncr.24572.
    [22] CHOI JH, OH D, LEE JH, et al. Initial human experience of endoscopic ultrasound-guided photodynamic therapy with a novel photosensitizer and a flexible laser-light catheter[J]. Endoscopy, 2015, 47(11): 1035-1038. DOI: 10.1055/s-0034-1392150.
    [23] AMBLARD I, MERCIER F, BARTLETT DL, et al. Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups[J]. Eur J Surg Oncol, 2018, 44(9): 1378-1383. DOI: 10.1016/j.ejso.2018.04.023.
    [24] HERNANDEZ DL, RESTREPO J, GARCIA MORA M. Peritoneal metastasis of cholangiocarcinoma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at the instituto nacional de cancerología, Colombia[J]. Cureus, 2020, 12(1): e6697. DOI: 10.7759/cureus.6697.
    [25] VALLE J, WASAN H, PALMER DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14): 1273-1281. DOI: 10.1056/NEJMoa0908721.
    [26] VALLE JW, FURUSE J, JITLAL M, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: A meta-analysis of two randomised trials[J]. Ann Oncol, 2014, 25(2): 391-398. DOI: 10.1093/annonc/mdt540.
    [27] MIZUSAWA J, MORIZANE C, OKUSAKA T, et al. Randomized phase Ⅲ study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT)[J]. Jpn J Clin Oncol, 2016, 46(4): 385-388. DOI: 10.1093/jjco/hyv213.
    [28] SHROFF RT, JAVLE MM, XIAO L, et al. Gemcitabine, cisplatin, and nab-Paclitaxel for the treatment of advanced biliary tract cancers: A phase 2 clinical trial[J]. JAMA Oncol, 2019, 5(6): 824-830. DOI: 10.1001/jamaoncol.2019.0270.
    [29] LAMARCA A, PALMER DH, WASSAN HS, et al. ABC-06 | A randomised phase Ⅲ, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy[J]. J Clin Oncol, 2019, 37: 4003.
    [30] PRIMROSE JN, FOX RP, PALMER DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): A randomised, controlled, multicentre, phase 3 study[J]. Lancet Oncol, 2019, 20(5): 663-673. DOI: 10.1016/S1470-2045(18)30915-X.
    [31] NAKAMURA H, ARAI Y, TOTOKI Y, et al. Genomic spectra of biliary tract cancer[J]. Nat Genet, 2015, 47(9): 1003-1010. DOI: 10.1038/ng.3375.
    [32] MONTAL R, SIA D, MONTIRONI C, et al. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma[J]. J Hepatol, 2020, 73(2): 315-327. DOI: 10.1016/j.jhep.2020.03.008.
    [33] LOEFFLER MA, HU J, KIRCHNER M, et al. miRNA profiling of biliary intraepithelial neoplasia reveals stepwise tumorigenesis in distal cholangiocarcinoma via the miR-451a/ATF2 axis[J]. J Pathol, 2020, 252(3): 239-251. DOI: 10.1002/path.5514.
    [34] DRILON A, SIENA S, OU SI, et al. Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor Entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1)[J]. Cancer Discov, 2017, 7(4): 400-409. DOI: 10.1158/2159-8290.CD-16-1237.
    [35] DOEBELE RC, DRILON A, PAZ-ARES L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials[J]. Lancet Oncol, 2020, 21(2): 271-282. DOI: 10.1016/S1470-2045(19)30691-6.
    [36] LE DT, DURHAM JN, SMITH KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J]. Science, 2017, 357(6349): 409-413. DOI: 10.1126/science.aan6733.
    [37] ABOU-ALFA GK, SAHAI V, HOLLEBECQUE A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study[J]. Lancet Oncol, 2020, 21(5): 671-684. DOI: 10.1016/S1470-2045(20)30109-1.
    [38] ABOU-ALFA GK, MACARULLA T, JAVLE MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(6): 796-807. DOI: 10.1016/S1470-2045(20)30157-1.
    [39] LEE J, PARK SH, CHANG HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: A multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2012, 13(2): 181-188. DOI: 10.1016/S1470-2045(11)70301-1.
    [40] CHANG J, GU YC, LI XC. advances of immune checkpoint inhibitors in the treatment of cholangiocarcinoma[J]. Chin J Dig Surg, 2021, 20(2): 250-254. DOI: 10.3760/cma.j.cn115610-20210122-00037.

    长江, 顾轶超, 李相成. 胆管癌免疫检查点抑制剂治疗研究进展[J]. 中华消化外科杂志, 2021, 20(2): 250-254. DOI: 10.3760/cma.j.cn115610-20210122-00037.
    [41] KANG J, JEONG JH, HWANG HS, et al. Efficacy and safety of pembrolizumab in patients with refractory advanced biliary tract cancer: Tumor proportion score as a potential biomarker for response[J]. Cancer Res Treat, 2020, 52(2): 594-603. DOI: 10.4143/crt.2019.493.
    [42] LEE SH, LEE HS, LEE SH, et al. Efficacy and safety of pembrolizumab for gemcitabine/cisplatin-refractory biliary tract cancer: A multicenter retrospective study[J]. J Clin Med, 2020, 9(6): 1769. DOI: 10.3390/jcm9061769.
    [43] KIM RD, CHUNG V, ALESE OB, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer[J]. JAMA Oncol, 2020, 6(6): 888-894. DOI: 10.1001/jamaoncol.2020.0930.
    [44] FENG K, LIU Y, ZHAO Y, et al. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: Results from a phase Ⅱ study[J]. J Immunother Cancer, 2020, 8(1): e000367. DOI: 10.1136/jitc-2019-000367.
    [45] XIE C, DUFFY AG, MABRY-HRONES D, et al. Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer[J]. Hepatology, 2019, 69(5): 2048-2060. DOI: 10.1002/hep.30482.
  • 加载中
计量
  • 文章访问数:  48
  • HTML全文浏览量:  17
  • PDF下载量:  11
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-12-20
  • 修回日期:  2021-02-18
  • 刊出日期:  2021-07-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回